AU2019221496B2 - Immunogenic composition comprising staphylococcal antigens - Google Patents

Immunogenic composition comprising staphylococcal antigens Download PDF

Info

Publication number
AU2019221496B2
AU2019221496B2 AU2019221496A AU2019221496A AU2019221496B2 AU 2019221496 B2 AU2019221496 B2 AU 2019221496B2 AU 2019221496 A AU2019221496 A AU 2019221496A AU 2019221496 A AU2019221496 A AU 2019221496A AU 2019221496 B2 AU2019221496 B2 AU 2019221496B2
Authority
AU
Australia
Prior art keywords
asn
lys
seq
asp
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2019221496A
Other languages
English (en)
Other versions
AU2019221496A1 (en
Inventor
Fabio Bagnoli
Carine Goraj
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of AU2019221496A1 publication Critical patent/AU2019221496A1/en
Application granted granted Critical
Publication of AU2019221496B2 publication Critical patent/AU2019221496B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2019221496A 2018-02-13 2019-02-12 Immunogenic composition comprising staphylococcal antigens Ceased AU2019221496B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1802339.0A GB201802339D0 (en) 2018-02-13 2018-02-13 Immunogenic composition
GB1802339.0 2018-02-13
PCT/EP2019/053463 WO2019158537A1 (en) 2018-02-13 2019-02-12 Immunogenic composition comprising staphylococcal antigens

Publications (2)

Publication Number Publication Date
AU2019221496A1 AU2019221496A1 (en) 2020-08-27
AU2019221496B2 true AU2019221496B2 (en) 2022-12-08

Family

ID=61731342

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019221496A Ceased AU2019221496B2 (en) 2018-02-13 2019-02-12 Immunogenic composition comprising staphylococcal antigens

Country Status (15)

Country Link
US (2) US11426455B2 (https=)
EP (1) EP3752183A1 (https=)
JP (1) JP2021514387A (https=)
KR (1) KR20200121825A (https=)
CN (1) CN112153980A (https=)
AR (1) AR114627A1 (https=)
AU (1) AU2019221496B2 (https=)
BR (1) BR112020016373A2 (https=)
CA (1) CA3090609A1 (https=)
EA (1) EA202091690A1 (https=)
GB (1) GB201802339D0 (https=)
IL (1) IL276661B2 (https=)
MX (1) MX2020008454A (https=)
SG (1) SG11202007676RA (https=)
WO (1) WO2019158537A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201721582D0 (en) * 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
CN110511950B (zh) * 2019-07-29 2022-03-08 因之彩生物科技（武汉）有限公司 Pab蛋白在构建具有类伴侣样蛋白作用的融合蛋白表达载体中的应用
EP3777884A1 (en) * 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
WO2021122551A1 (en) 2019-12-19 2021-06-24 Glaxosmithkline Biologicals Sa S. aureus antigens and compositions thereof
MY207887A (en) * 2020-05-01 2025-03-26 Sinocelltech Ltd Method for improving immunogenicity of protein/peptide antigen
JP7423133B2 (ja) 2020-09-21 2024-01-29 エルジー エナジー ソリューション リミテッド リチウム二次電池の活性化方法及びリチウム二次電池

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010151544A1 (en) * 2009-06-22 2010-12-29 Wyeth Llc Immunogenic compositions of staphylococcus aureus antigens
WO2012003474A2 (en) * 2010-07-02 2012-01-05 The University Of Chicago Compositions and methods related to protein a (spa) variants

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ553776A (en) * 2004-09-22 2010-05-28 Glaxosmithkline Biolog Sa Immunogenic composition comprising staphylococcal PNAG and Type 5 and/or 8 Capsular polysaccharide or oligosaccharide.
GB0526038D0 (en) 2005-12-21 2006-02-01 Glaxosmithkline Biolog Sa Immunogenic composition
SG188102A1 (en) * 2008-01-31 2013-03-28 Trinity College Dublin Treatment of microbial infections
AU2015202532A1 (en) 2009-04-14 2015-06-04 Novartis Ag Compositions for immunising against Staphylococcus aureus
US20140037650A1 (en) 2009-07-24 2014-02-06 University Of Chicago Compositions and methods related to antibodies to staphylococcal proteins isda or isdb
EP3281639B1 (en) * 2010-05-06 2020-11-11 GlaxoSmithKline Biologicals S.A. Capsular gram-positive bacteria bioconjugate vaccines
EP2614074A1 (en) 2010-09-09 2013-07-17 The University of Chicago Methods and compositions involving protective staphylococcal antigens
EP2654784B1 (en) 2010-12-22 2016-12-07 Wyeth LLC Stable immunogenic compositions of staphylococcus aureus antigens
BR112014003315A2 (pt) * 2011-08-15 2017-03-01 Univ Chicago composições e métodos relacionados a anticorpos para a proteína a estafilocócica
US20150202277A1 (en) * 2012-08-31 2015-07-23 Novartis Ag Stabilised proteins for immunising against staphylococcus aureus
US10195262B2 (en) 2013-12-04 2019-02-05 Glaxosmithkline Biologicals S.A. Prevention of Staphylococcus aureus infections by glycoprotein vaccines synthesized in Escherichia coli
CN106103469B (zh) * 2014-03-26 2020-11-27 葛兰素史密丝克莱恩生物有限公司 突变型葡萄球菌抗原
GB201721576D0 (en) * 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
GB201721582D0 (en) * 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010151544A1 (en) * 2009-06-22 2010-12-29 Wyeth Llc Immunogenic compositions of staphylococcus aureus antigens
WO2012003474A2 (en) * 2010-07-02 2012-01-05 The University Of Chicago Compositions and methods related to protein a (spa) variants

Also Published As

Publication number Publication date
US11426455B2 (en) 2022-08-30
EA202091690A1 (ru) 2020-11-27
US20230052495A1 (en) 2023-02-16
WO2019158537A1 (en) 2019-08-22
CN112153980A (zh) 2020-12-29
KR20200121825A (ko) 2020-10-26
IL276661B2 (en) 2023-08-01
EP3752183A1 (en) 2020-12-23
US20210023192A1 (en) 2021-01-28
MX2020008454A (es) 2021-03-25
AR114627A1 (es) 2020-09-30
CA3090609A1 (en) 2019-08-22
AU2019221496A1 (en) 2020-08-27
BR112020016373A2 (pt) 2020-12-15
GB201802339D0 (en) 2018-03-28
IL276661A (en) 2020-09-30
IL276661B1 (en) 2023-04-01
SG11202007676RA (en) 2020-09-29
JP2021514387A (ja) 2021-06-10

Similar Documents

Publication Publication Date Title
AU2019221496B2 (en) Immunogenic composition comprising staphylococcal antigens
US11466058B2 (en) Mutant fragments of OspA and methods and uses relating thereto
US11819544B2 (en) Immunogenic composition
CN106103469B (zh) 突变型葡萄球菌抗原
JP2021528059A (ja) グリコシル化されたＣｏｍＰピリンバリアント、製造方法及びその使用
CA3086262A1 (en) Immunogenic composition
US20220395566A1 (en) Immunogenic composition
JP7511188B2 (ja) 複合糖質ワクチン
HK40047921A (en) Mutant staphylococcal antigens
HK1207982B (en) Mutant fragments of ospa and methods and uses relating thereto
EA046886B1 (ru) МУТАНТНЫЕ ФРАГМЕНТЫ OspA И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И ПРИМЕНЕНИЕ

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired